Zobrazeno 1 - 10
of 68
pro vyhledávání: '"Ofer Rotem"'
Autor:
Ofer Rotem, Karyn Revital Geiger, Ekaterina Hanovich, Mor Moskovitz, Noga Kurman, Daniel Reinhorn, Idit Peretz, Rinat Yerushalmi, Salomon M. Stemmer
Publikováno v:
Oncology Reviews, Vol 18 (2024)
As clinical trials in oncology require substantial efforts, maximizing the insights gained from them by conducting subgroup analyses is often attempted. The goal of these analyses is to identify subgroups of patients who are likely to benefit, as wel
Externí odkaz:
https://doaj.org/article/18f293ed166a48a39dded36cb9ce5bf3
Autor:
Itamar Averbuch, Roi Tschernichovsky, Oded Icht, Daniel A. Goldstein, Raz Mutai, Elizabeth Dudnik, Ofer Rotem, Nir Peled, Aaron M. Allen, Smadar Laufer‐Geva, Yael Goldberg, Alona Zer
Publikováno v:
Thoracic Cancer, Vol 14, Iss 17, Pp 1589-1596 (2023)
Abstract Background Mutations in genes involved in DNA damage repair (DDR), a hallmark of cancer, are associated with increased cancer cell sensitivity to certain therapies. This study sought to evaluate the association of DDR pathogenic variants wit
Externí odkaz:
https://doaj.org/article/b459005a45264617bf9d0dca54eb2f87
Autor:
Ofer Rotem, Idit Peretz, Michelle Leviov, Iryna Kuchuk, Amit Itay, Margarita Tokar, Shani Paluch-Shimon, Ofra Maimon, Rinat Yerushalmi, Karen Drumea, Ella Evron, Amir Sonnenblick, Einav Gal-Yam, Hadar Goldvaser, Yosef Samih, Rotem Merose, Avital Bareket-Samish, Lior Soussan-Gutman, Salomon M. Stemmer
Publikováno v:
npj Breast Cancer, Vol 9, Iss 1, Pp 1-8 (2023)
Abstract Data on adjuvant chemotherapy (CT) benefit in ER + HER2‒ early-stage breast cancer (EBC) patients with Recurrence Score (RS) 26-30 are limited. This real-world study evaluated the relationships between the RS, adjuvant treatments, and outc
Externí odkaz:
https://doaj.org/article/ee418dc5761c458bb5099fc02f2cafa0
Autor:
Ofer Rotem, Alona Zer, Lilach Yosef, Einat Beery, Hadar Goldvaser, Anna Gutkin, Ron Levin, Elizabeth Dudnik, Tamar Berger, Meora Feinmesser, Adva Levy-Barda, Meir Lahav, Pia Raanani, Orit Uziel
Publikováno v:
Biomedicines, Vol 11, Iss 6, p 1730 (2023)
Background: Telomerase (human telomerase reverse transcriptase (hTERT) is considered a hallmark of cancer, being active in cancer cells but repressed in human somatic cells. As such, it has the potential to serve as a valid cancer biomarker. Exosomal
Externí odkaz:
https://doaj.org/article/ea1388e29b884de499c59b7b8616bd93
Autor:
Oliver Illini, Hannah Fabikan, Aurélie Swalduz, Anders Vikström, Dagmar Krenbek, Michael Schumacher, Elizabeth Dudnik, Michael Studnicka, Ronny Öhman, Robert Wurm, Luciano Wannesson, Nir Peled, Waleed Kian, Jair Bar, Sameh Daher, Alfredo Addeo, Ofer Rotem, Georg Pall, Alona Zer, Akram Saad, Tanja Cufer, Hadas Gantz Sorotsky, Sayed M. S. Hashemi, Katja Mohorcic, Ronen Stoff, Yulia Rovitsky, Shoshana Keren-Rosenberg, Thomas Winder, Christoph Weinlinger, Arschang Valipour, Maximilian J. Hochmair
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 14 (2022)
Background: Patients with non-small cell lung cancer (NSCLC) presenting with mesenchymal–epithelial transition ( MET ) exon 14 skipping mutation have an unfavorable prognosis with standard treatments. Capmatinib is a selective MET inhibitor, which
Externí odkaz:
https://doaj.org/article/0bbcd42c11e74cbfb91361945db11f28
Autor:
Michal Sternschuss, Nir Peled, Aaron M. Allen, Elizabeth Dudnik, Ofer Rotem, Noga Kurman, Omer Gal, Hiba Reches, Alona Zer
Publikováno v:
Thoracic Cancer, Vol 11, Iss 8, Pp 2331-2334 (2020)
Anti‐PD‐1/PD‐L1 agents play a crucial part in the treatment of non‐small cell cancer (NSCLC) demonstrating improved overall response rate (ORR) and overall survival (OS). Recent studies evaluating combination treatment with anti‐PD‐1 and
Externí odkaz:
https://doaj.org/article/b2bfa9d7745e42549862340cfd51a3d1
Autor:
Elizabeth Dudnik, Jair Bar, Assaf Moore, Teodor Gottfried, Mor Moskovitz, Julia Dudnik, Tzippy Shochat, Aaron M. Allen, Alona Zer, Ofer Rotem, Nir Peled, Damien Urban
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
ObjectivesLittle is known regarding the outcomes of systemic treatments in BAP1-altered malignant pleural mesothelioma (MPM).Materials and MethodsForty five patients with MPM [group A: eight MPM patients with BAP1 inactivating mutation/copy number lo
Externí odkaz:
https://doaj.org/article/3a22bf6714734771a3834ddc2e05cc4b
Autor:
Stephen V Liu, Elizabeth Dudnik, Mor Moskovitz, Anastasiya Lobachov, Teodor Gottfried, Damien Urban, Ofer Rotem, Mira Wollner
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 2 (2021)
Background Little is known regarding the efficacy of immune checkpoint inhibitors (ICI) in patients with advanced large-cell neuroendocrine lung carcinoma (aLCNEC).Methods 125 consecutive patients with aLCNEC were identified in the electronic databas
Externí odkaz:
https://doaj.org/article/b4a8ed4bacae4a4eb4687cec2aca3a89
Autor:
Elizabeth Dudnik, Mor Moskovitz, Yakir Rottenberg, Anastasiya Lobachov, Rinat Mandelboim, Tzippy Shochat, Damien Urban, Mira Wollner, Hovav Nechushtan, Ofer Rotem, Alona Zer, Sameh Daher, Jair Bar, On behalf of the Israel Lung Cancer Group
Publikováno v:
OncoImmunology, Vol 10, Iss 1 (2021)
Both pembrolizumab (P) and combination of pembrolizumab with platinum-based chemotherapy (PCT) represent standard 1st-line options for advanced non-small cell lung cancer (aNSCLC) with PD-L1 tumor proportion score (TPS) ≥50%. The two strategies hav
Externí odkaz:
https://doaj.org/article/44c1cb5fec14475bbf1fe6dd6c30db09
Autor:
Yosef Landman, Oded Jacobi, Noga Kurman, Orly Yariv, Idit Peretz, Ofer Rotem, Elizabeth Dudnik, Alona Zer, Aaron M. Allen
Publikováno v:
OncoImmunology, Vol 10, Iss 1 (2021)
The standard of care for stage III non-small cell lung cancer (NSCLC) is chemoradiotherapy (CRT) followed by durvalumab. Although doses higher than 66 Gy are standard in our center, they were used in only 6.9% of patients in the PACIFIC trial. We rep
Externí odkaz:
https://doaj.org/article/137b1d142eab40229a53b83577ea701c